Sutro Biopharma, Inc.
STRO
$0.9026
-$0.3974-30.57%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 62.04M | 160.96M | 169.36M | 154.07M | 153.73M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 62.04M | 160.96M | 169.36M | 154.07M | 153.73M |
| Cost of Revenue | 12.50M | 66.18M | 49.74M | 29.31M | 11.83M |
| Gross Profit | 49.54M | 94.78M | 119.62M | 124.75M | 141.90M |
| SG&A Expenses | 48.45M | 56.23M | 57.17M | 59.79M | 62.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 300.50M | 291.00M | 275.50M | 257.70M | 243.01M |
| Operating Income | -238.45M | -130.04M | -106.14M | -103.63M | -89.28M |
| Income Before Tax | -225.10M | -108.14M | -106.80M | -97.16M | -88.60M |
| Income Tax Expenses | 2.36M | 15.82M | 17.65M | 17.80M | 18.19M |
| Earnings from Continuing Operations | -227.46 | -123.95 | -124.45 | -114.96 | -106.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -227.46M | -123.95M | -124.45M | -114.96M | -106.79M |
| EBIT | -238.45M | -130.04M | -106.14M | -103.63M | -89.28M |
| EBITDA | -231.24M | -122.96M | -99.12M | -96.67M | -82.46M |
| EPS Basic | -3.01 | -1.62 | -1.84 | -1.89 | -1.79 |
| Normalized Basic EPS | -2.12 | -1.19 | -1.13 | -1.21 | -1.03 |
| EPS Diluted | -3.01 | -1.62 | -1.84 | -1.89 | -1.79 |
| Normalized Diluted EPS | -2.12 | -1.19 | -1.13 | -1.21 | -1.03 |
| Average Basic Shares Outstanding | 307.24M | 285.70M | 264.25M | 243.37M | 240.63M |
| Average Diluted Shares Outstanding | 307.24M | 285.70M | 264.25M | 243.37M | 240.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |